Literature DB >> 19132536

Change in criteria for USP dissolution performance verification tests.

Walter W Hauck1, Anthony J DeStefano, William E Brown, Erika S Stippler, Darrell R Abernethy, William F Koch, Roger L Williams.   

Abstract

The US Pharmacopeial Convention has been evaluating its performance verification tests (PVT) for several years. These tests help ensure the integrity of the US Pharmacopeia performance test when a dissolution procedure, as described in General Chapter Dissolution <711>, is relied upon to test a nonsolution orally administered dosage form. One result of the evaluation is a change in the PVT criterion from one based on individual tablet results to one based on the mean and variability of a set of tablets. This paper describes the new PVT and its criterion and how its acceptance limits are derived from results of a collaborative study, explains a two-stage option for the test, and presents operating characteristics.

Mesh:

Substances:

Year:  2009        PMID: 19132536      PMCID: PMC2663662          DOI: 10.1208/s12249-008-9169-y

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  3 in total

1.  The USP Performance Verification Test, Part II: collaborative study of USP's Lot P Prednisone Tablets.

Authors:  Maria Glasgow; Shawn Dressman; William Brown; Thomas Foster; Stefan Schuber; Ronald G Manning; Samir Z Wahab; Roger L Williams; Walter W Hauck
Journal:  Pharm Res       Date:  2008-01-03       Impact factor: 4.200

2.  A multiple testing procedure for clinical trials.

Authors:  P C O'Brien; T R Fleming
Journal:  Biometrics       Date:  1979-09       Impact factor: 2.571

3.  The USP Performance Verification Test, Part I: USP Lot P Prednisone Tablets: quality attributes and experimental variables contributing to dissolution variance.

Authors:  Gang Deng; Alyssa J Ashley; William E Brown; Joseph W Eaton; Walter W Hauck; Loice C Kikwai; Mark R Liddell; Ronald G Manning; Jimmy M Munoz; Pallavi Nithyanandan; Maria J Glasgow; Erika Stippler; Samir Z Wahab; Roger L Williams
Journal:  Pharm Res       Date:  2008-01-03       Impact factor: 4.200

  3 in total
  1 in total

1.  Establishing new acceptance limits for dissolution performance verification of USPC apparatus 1 and 2 using USPC prednisone tablets reference standard.

Authors:  Anthony J DeStefano; Walter W Hauck; Erika S Stippler; William E Brown; Chensheng Li; Gloria G Huang; Barbara J Jones; Kevin O'Hool; William F Koch; Roger L Williams
Journal:  Pharm Res       Date:  2010-10-16       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.